Intrinsiqq
Pharvaris N.V. logo

Pharvaris N.V. Insider Trading

PHVS

Compare
Last 12 months

Insiders sold $33M and bought nothing on the open market.

48% of the selling was scheduled in advance under 10b5-1 plans. Director Johannes Gerardus Christiaan Petrus Schikan sold $7M on Sep 17, 63% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market
−$33M
0 buys · 43 sales
Under a 10b5-1 plan
48%
of the value sold
Insiders who bought / sold
0 / 11
executives and directors
Last open-market buy
None
in the last two years

Get an email when PHVS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 23No plan
    Viviane Monges
    Director · sold 11,969 at $33.05
    396K
    69% of stake
  • Sep 22No plan
    Johannes Gerardus Christiaan Petrus Schikan
    Director · sold 800 at $36.19
    29K
    0.7% of stake
  • Sep 21No plan
    David W. Nassif
    CFO / CLO · sold 6,000 at $36.47
    219K
    5.0% of stake
  • Sep 17No plan
    Peng Lu
    President · sold 100,000 at $35.00
    $3.5M
    61% of stake
  • Sep 17No plan
    Johannes Gerardus Christiaan Petrus Schikan
    Director · sold 200,000 at $35.00
    $7M
    63% of stake
  • Sep 17No plan
    Elisabeth Bjork
    Director · sold 52,500 at $37.89
    $1.99M
    78% of stake
  • Sep 1710b5-1 plan
    Robert Glassman
    Director · sold 14,493 at $38.56
    559K
    58% of stake
  • Sep 17No plan
    Anne Lesage
    Chief Early Development · sold 20,000 at $38.27
    765K
    13% of stake
  • Sep 15No plan
    Stefan Andreas Abele
    Chief Technical Ops Officer · sold 46,400 at avg $38.17
    $1.77M
    54% of stake
  • Sep 1510b5-1 plan
    Robert Glassman
    Director · sold 8,667 at $38.27
    332K
    45% of stake
  • Sep 14 – 1510b5-1 plan
    Wim Souverijns
    Chief Commercial Officer · sold 26,090 at avg $39.24
    $1.02M
    40% of stake
  • Sep 1410b5-1 plan
    Berndt Modig
    Chief Executive Officer · sold 2,291 at $39.40
    90K
    0.2% of stake
  • Sep 1110b5-1 plan
    Peng Lu
    President · sold 15,000 at $40.13
    602K
    19% of stake
  • Sep 1010b5-1 plan
    Anne Lesage
    Chief Early Development · sold 30,000 at $38.30
    $1.15M
    35% of stake
  • Sep 910b5-1 plan
    Robert Glassman
    Director · sold 8,000 at $37.55
    300K
    43% of stake
  • Sep 810b5-1 plan
    Peng Lu
    President · sold 15,000 at $40.68
    610K
    19% of stake
  • Aug 1410b5-1 plan
    Berndt Modig
    Chief Executive Officer · sold 2,292 at $34.77
    80K
    0.2% of stake
  • Jul 1310b5-1 plan
    Berndt Modig
    Chief Executive Officer · sold 2,292 at $34.97
    80K
    0.2% of stake
  • Jun 29 – 3010b5-1 plan
    Johannes Gerardus Christiaan Petrus Schikan
    Director · sold 37,600 at avg $35.41
    $1.33M
    11% of stake
  • Jun 29 – 3010b5-1 plan
    Anne Lesage
    Chief Early Development · sold 76,172 at avg $35.39
    $2.7M
    33% of stake
  • Jun 2910b5-1 plan
    Johannes Gerardus Christiaan Petrus Schikan
    Director · sold 2,400 at $35.10
    84K
    0.7% of stake
  • Jun 25 – 2610b5-1 plan
    Peng Lu
    Chief Medical Officer · sold 29,700 at avg $34.30
    $1.02M
    31% of stake
  • Jun 2510b5-1 plan
    Anne Lesage
    Chief Early Development · sold 4,600 at avg $35.12
    162K
    2.4% of stake
  • Jun 1810b5-1 plan
    Peng Lu
    Chief Medical Officer · sold 300 at $34.00
    10K
    0.5% of stake
  • Jun 1510b5-1 plan
    Berndt Modig
    Chief Executive Officer · sold 2,291 at avg $31.07
    71K
    0.2% of stake
  • Jun 4No plan
    Anna Nijdam
    Principal Accounting Officer · sold 2,670 at $30.87
    82K
    5.5% of stake
  • May 21 – 22No plan
    Anna Nijdam
    Principal Accounting Officer · sold 7,330 at avg $30.71
    225K
    13% of stake
  • May 21No plan
    Viviane Monges
    Director · sold 9,667 at $30.29
    293K
    64% of stake
  • May 21No plan
    David W. Nassif
    CFO / CLO · sold 10,000 at $30.31
    303K
    7.7% of stake
  • May 2010b5-1 plan
    Elisabeth Bjork
    Director · sold 10,000 at $29.32
    293K
    40% of stake
  • May 1810b5-1 plan
    Berndt Modig
    Chief Executive Officer · sold 2,292 at $29.22
    67K
    1.6% of stake
  • May 15No plan
    Robert Glassman
    Director · sold 10,000 at avg $29.83
    298K
    49% of stake
  • May 15No plan
    Stefan Andreas Abele
    Chief Technical Ops Officer · sold 8,748 at $29.82
    261K
    20% of stake
  • May 1510b5-1 plan
    Wim Souverijns
    Chief Commercial Officer · sold 10,000 at $29.92
    299K
    18% of stake
  • May 110b5-1 plan
    Peng Lu
    Chief Medical Officer · sold 14,166 at avg $30.17
    427K
    18% of stake
  • Apr 29 – 3010b5-1 plan
    Johannes Gerardus Christiaan Petrus Schikan
    Director · sold 32,900 at avg $30.29
    996K
    8.5% of stake
  • Apr 29 – 3010b5-1 plan
    Anne Lesage
    Chief Early Development · sold 48,300 at avg $30.23
    $1.46M
    20% of stake
  • Apr 29 – 3010b5-1 plan
    Peng Lu
    Chief Medical Officer · sold 18,733 at avg $30.20
    566K
    22% of stake
  • Apr 22 – 2310b5-1 plan
    Johannes Gerardus Christiaan Petrus Schikan
    Director · sold 7,100 at avg $30.05
    213K
    1.8% of stake
  • Apr 22 – 2310b5-1 plan
    Anne Lesage
    Chief Early Development · sold 14,700 at avg $30.05
    442K
    6.4% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PHVS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biotechnology · Pick stocks to compare with PHVS

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Held by ETFs

PHVS is in 16 US ETFs. The largest of them, with PHVS's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PHVS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.